Drugs Made In America Acquisition Corp. (DMAAU) Accounts Payables (2024 - 2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Accounts Payables came in at $222184.0 in Q4 2025, up 187.51% YoY from $77280.0 in Q4 2024, and up 22118.4% on a QoQ basis from $1000.0 in Q2 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Accounts Payables (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 2 years of Accounts Payables data on file, last reported at $222184.0 in Q4 2025.
- Quarterly Accounts Payables rose 187.51% year-over-year to $222184.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $222184.0 (up 187.51% YoY) and the FY2025 annual result came in at $222184.0, up 187.51% from the prior year.
- Accounts Payables advanced to $222184.0 in Q4 2025, from $1000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $222184.0 in Q4 2025 to a low of $1000.0 in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 222,184.00 |
| Jun 30, 2025 | 1,000.00 |
| Dec 31, 2024 | 77,280.00 |